📖

ALS-FTD Spectrum

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-als-ftd-spectrum

Related Entities

Metadata

slug	diseases-als-ftd-spectrum
entity_type	disease
kg_node_id	None

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (141)

mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di75%

mentions🔬RNA binding protein dysregulation across ALS FTD AD75%

mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes75%

mentions🔬RNA binding protein dysregulation across ALS FTD and AD75%

mentions🧫cGAMP biomarker analysis in ALS patient spinal cord samples70%

mentions🧫TDP-43 mutant mouse model cGAS/STING pathway analysis70%

mentions🧫cGAMP biomarker analysis in ALS patient spinal cord samples70%

mentions🧫TDP-43 mitochondrial invasion and mtDNA release in iPSC moto70%

mentions🧫cGAS/STING pathway activation by TDP-43-released mtDNA70%

mentions🧫s:** - Temporal analysis showing mitochondrial defects prece70%

mentions🧫Proposed experiment from debate on TDP-43 undergoes liquid-l70%

mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr70%

mentions🧫Metabolic Pathway-Targeted Therapy in ALS70%

mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker70%

mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model70%

mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk70%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%

mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration70%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%

mentions🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka70%

mentions🧫Brainstem Circuit Modulation for PSP70%

mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT70%

mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study70%

mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen70%

mentions🧫Experiment Index70%

mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio70%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design70%

mentions🧫Multiscale Computational Modeling of Protein Aggregation Kin70%

mentions🧫N-of-1 Clinical Trial Design for CBS/PSP70%

mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic70%

mentions🧫Progranulin Replacement Therapy for FTD — Vector Development70%

mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD70%

mentions🧫PSP and CBS Biomarker Validation Study70%

mentions🧫Experiment Scoring Methodology70%

mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen70%

mentions🧫TDP-43 PET Ligand Development for FTD and ALS70%

mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%

related🧫Cytochrome Therapeutics70%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration70%

related🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M70%

related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud70%

related🧫Progranulin Replacement Therapy for FTD — Vector Development70%

related🧫Cytochrome Therapeutics70%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration70%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT70%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study70%

related🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M70%

related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud70%

related🧫Progranulin Replacement Therapy for FTD — Vector Development70%

related🔬CRISPR-based therapeutic approaches for neurodegenerative di67%

related🔬RNA binding protein dysregulation across ALS FTD AD67%

related🔬TDP-43 undergoes liquid-liquid phase separation that becomes67%

related🔬RNA binding protein dysregulation across ALS FTD and AD67%

related🧫cGAMP biomarker analysis in ALS patient spinal cord samples63%

related🧫TDP-43 mutant mouse model cGAS/STING pathway analysis63%

related🧫cGAMP biomarker analysis in ALS patient spinal cord samples63%

related🧫TDP-43 mitochondrial invasion and mtDNA release in iPSC moto63%

related🧫cGAS/STING pathway activation by TDP-43-released mtDNA63%

related🧫s:** - Temporal analysis showing mitochondrial defects prece63%

related🧫Proposed experiment from debate on TDP-43 undergoes liquid-l63%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr63%

related🧫Metabolic Pathway-Targeted Therapy in ALS63%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker63%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model63%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk63%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring63%

related🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka63%

related🧫Brainstem Circuit Modulation for PSP63%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT63%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study63%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen63%

related🧫Experiment Index63%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio63%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design63%

related🧫Multiscale Computational Modeling of Protein Aggregation Kin63%

related🧫N-of-1 Clinical Trial Design for CBS/PSP63%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic63%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD63%

related🧫PSP and CBS Biomarker Validation Study63%

related🧫Experiment Scoring Methodology63%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen63%

related🧫TDP-43 PET Ligand Development for FTD and ALS63%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des63%

mentions🧪Cryptic Exon Silencing Restoration60%

mentions🧪Glycine-Rich Domain Competitive Inhibition60%

mentions🧪Cross-Seeding Prevention Strategy60%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t60%

mentions🔬What are the mechanisms underlying rna binding protein dysre60%

mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di60%

mentions🔬Analyze the spectrum of microglial activation states (DAM, h60%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%

related🧫Metabolic Pathway-Targeted Therapy in ALS60%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%

related🧫Brainstem Circuit Modulation for PSP60%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%

related🧫N-of-1 Clinical Trial Design for CBS/PSP60%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%

related🧫PSP and CBS Biomarker Validation Study60%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%

related🧫TDP-43 PET Ligand Development for FTD and ALS60%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%

related🧪Cryptic Exon Silencing Restoration54%

related🧪Glycine-Rich Domain Competitive Inhibition54%

related🧪Cross-Seeding Prevention Strategy54%

related🔬What are the mechanisms underlying tdp-43 phase separation t54%

related🔬What are the mechanisms underlying rna binding protein dysre54%

related🔬CRISPR-based therapeutic approaches for neurodegenerative di54%

related🔬Analyze the spectrum of microglial activation states (DAM, h54%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%

mentions🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying protein aggregation cross50%

related🔬How does metabolic reprogramming (glucose metabolism shifts,50%

related🧪Mitochondrial-Lysosomal Contact Site Engineering50%

related🧪Lysosomal Membrane Repair Enhancement50%

related🧪Lysosomal Calcium Channel Modulation Therapy50%

related🧪Lysosomal Enzyme Trafficking Correction50%

related🧪Axonal RNA Transport Reconstitution50%

related🧪Serine/Arginine-Rich Protein Kinase Modulation50%

related🧪Stress Granule Phase Separation Modulators50%

related🧪Phase-Separated Organelle Targeting50%

related🧪RNA Granule Nucleation Site Modulation50%

related🧪Lysosomal Positioning Dynamics Modulation50%

mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation44%

mentions🧫Microtubule domain analysis in adult axons44%

mentions🧫Tau depletion effects on neuronal development in primary cul44%

mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers44%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa40%

mentions🔬What are the mechanisms underlying protein aggregation cross40%

mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%